Ref ID: 18773
Author:
J. Pupaibool, MD (Doctor of Medicine) – Infectious Diseases Fellow, T. J. Kottom, MS – Instructor in Biochem/Molecular Biology, A. H. Limper, MD – Professor;
Author address:
Mayo Clinic, Rochester, MN.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: To date, all clinically effective drugs for opportunistic fungi are limited because it is difficult to identify fungi-specific molecular targets with no adverse effects on humans. Rtt109 is a fungal histone acetyltransferase (HAT) which acetylates histone H3 lysine 56. It is essential for Saccharomyces cerevisiae to survive in the presence of DNA-damaging agents. Rtt109 is conserved among fungal species, but it is quite diverged from mammalian HATs. Thus, it may represent an attractive target for anti-fungal therapy. We evaluated biochemical activities of an Rtt109 inhibitor, GPHR32548, with Pneumocystis Rtt109 (PcRtt109) and Aspergillus Rtt109 (AsRtt109). Methods: We incubated 1 µg of PcRtt109 and AsRtt109 with different concentrations of GPHR32548 before adding chicken histone (H3/H4) tetramers and [3H]acetyl-coenzyme A. Reaction mixtures are spotted onto P-81 phosphocellulose paper filters. The paper filters were air-dried and washed, then the radioactivity of [3H]-acetylated histones was measured. We also resolved the reaction mixtures using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were dried and exposed to films. Results: GPHR32548 inhibited PcRtt109 and AsRtt109 in a dose-dependent fashion as demonstrated by autoradiography of [3H]-acetylated histones and dose-response curves (Figure 1). IC50 for PcRtt109 and AsRtt109 are 38.64 and 22.91 µM, respectively. Conclusions: GPHR32548 was shown to inhibit all fungal Rtt109 tested. The inhibition was species-independent. The results of our preliminary study indicate that Rtt109 is a potential target for anti-fungal therapy.
Abstract Number: F-813
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a